CRNX241220P38000
- 1.35
- 0.000.00%
Crinetics Newsroom
LifeSci Capital Maintains Crinetics(CRNX.US) With Buy Rating, Maintains Target Price $82
Promising Outlook for Crinetics Pharmaceuticals' Paltusotine in Phase 3 Trial Drives Buy Rating
Crinetics Pharmaceuticals to Participate in Three Upcoming December Investor Conferences
Crinetics Pharmaceuticals Third Quarter 2024 Earnings: US$0.96 Loss per Share (Vs US$1.01 Loss in 3Q 2023)
Citi Maintains Crinetics(CRNX.US) With Buy Rating, Raises Target Price to $74
Crinetics Pharmaceuticals: Promising Future With Innovative Drug Developments and Strong Financial Position
Crinetics Pharmaceuticals Analyst Ratings
JonesTrading Maintains Crinetics(CRNX.US) With Buy Rating, Maintains Target Price $71
Piper Sandler Maintains Crinetics(CRNX.US) With Buy Rating, Maintains Target Price $97
Piper Sandler Remains a Buy on Crinetics Pharmaceuticals (CRNX)
Morgan Stanley Maintains Crinetics(CRNX.US) With Buy Rating, Maintains Target Price $70
H.C. Wainwright Maintains Crinetics(CRNX.US) With Buy Rating, Raises Target Price to $81
Crinetics Price Target Raised to $81 From $69 at H.C. Wainwright
Crinetics Pharmaceuticals, Inc. (CRNX) Q3 2024 Earnings Call Transcript Summary
Crinetics Pharmaceuticals, Inc. (CRNX) Q3 2024 Earnings Call Transcript
LifeSci Capital Maintains Crinetics(CRNX.US) With Buy Rating, Raises Target Price to $82
Crinetics Pharmaceuticals: Advancing Cancer Treatment With Novel NDC Platform – A Buy Recommendation
Express News | Crinetics Expects That Its Cash & Equivalents To Be Sufficient To Fund Its Current Operating Plan Into 2029
Crinetics | 10-Q: Q3 2024 Earnings Report
Crinetics | 8-K: Crinetics Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update